Breakthrough of ADCs in breast cancer

Can't see this email? View it online

	Antibodies
	The latest antibodies news from News Medical

Another breakthrough of ADCs in breast cancer

The FDA has recently approved Enhertu (trastuzumab deruxtecan), the antibody-drug conjugate (ADC) of AstraZeneca and Daiichi Sankyo for patients with unresectable or metastatic HER2-positive breast cancer following one prior anti-HER2 therapy, either in the metastatic phase or in the early-stage setting. With this latest authorization, observers have suggested that Enhertu is likely to replace Kadcyla, the first-generation ADC, to treat HER2-positive breast cancer. ACROBiosystems has developed a range of products to meet your needs at every stage of your ADC development journey.

Learn More About ADC Products

Improving immunoassay development with liquid handling automation

Developing an immunoassay is challenging. Obtaining a specific signal requires the right combination of sample and detection substrate. In this application note, Formulatrix will show how the MANTIS^® liquid handler helped Cisbio to improve their immunoassay development process by increasing experiment reproducibility and reducing time and lab costs.

Download the free app note

How do Antibodies Cause Disease?

Antibodies are defensive molecules, part of the body’s adaptive immune response to pathogens. How are they involved in harming the same host they are produced by to defend it against foreign bodies and organisms?

	Neutralizing antibodies produced following COVID-19 BNT162b2 vaccine found to activate complement cascade Researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) produced following COVID-19 vaccination.

	Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals Researchers assessed the induction of variant-specific neutralizing antibodies against the SARS-CoV-2 spike and nucleocapsid proteins of several SARS-CoV-2 strains.

	Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants Researchers assessed the antibody responses elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and defined the epitopes shared by them.

	The sensitivity of Omicron subvariants to therapeutic monoclonal antibodies A new study evaluates the sensitivity of the new Omicron subvariants (BA.2.11, BA.2.12.1, and BA.4/5) to eight therapeutic mAbs

Website: www.news-medical.net

Email: [email protected]

Telephone: +44 (0)161 457 7150

AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

Why did you receive this email?
You recently requested related information from us and asked to be notified of additional information.

Not interested anymore?
Unsubscribe or
Update Your Newsletter Subscriptions